NASDAQ$ENTA
Enanta Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the fiscal first quarter ended December 31, 2022.
Enanta Pharmaceuticals reported revenue of $23.6 million for the quarter ended December 31, 2022, primarily from royalty revenue, and a net loss of $29.0 million, or $1.39 per diluted share. The company's cash, cash equivalents, and marketable securities totaled $241.4 million as of December 31, 2022.
- Completed enrollment in Phase 2 clinical study of EDP-235 for COVID-19, with topline data expected in May.
- Expect Phase 1 data of EDP-323 for Respiratory Syncytial Virus (RSV) in 2Q 2023.
- Expanded pipeline with new research programs developing SARS-CoV-2 Papain-Like Protease Inhibitors and Human Metapneumovirus (hMPV)/RSV Dual-Inhibitors.
- Revenue for the quarter was $23.6 million.
Headline financials
Revenue & EPS history
Enanta Pharmaceuticals · Revenue · Quarterly
$23.6M
Revenue by segment
Enanta Pharmaceuticals · $22.6M total across 1 segment · Q1 2023
- Royalty Revenue$22.6M-18.1%100.0%
Forward guidance
Enanta expects that its current cash, cash equivalents and marketable securities, as well as its continuing royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into the fourth fiscal quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-1.3%
Avg return
Earnings day
-1.2%
Avg return
5 days after
-1.0%
Avg return
30 days after
41%
24 / 58 earnings
Positive
+14.8%
Q4 2021
Best reaction
-29.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -6.1% | -13.4% | -26.0% | |
| Q1 2026 | +2.2% | +0.1% | -3.0% | |
| Q4 2025 | -3.5% | -0.7% | +13.3% | |
| Q2 2025 | -5.6% | +3.6% | +33.5% | |
| Q1 2025 | +14.1% | +45.7% | +39.4% | |
| Q4 2024 | -8.4% | -7.9% | -34.7% | |
| Q3 2024 | -6.5% | -9.5% | -12.7% | |
| Q2 2024 | -13.6% | -16.6% | -18.3% | |
| Q1 2024 | -1.4% | -1.7% | +22.8% | |
| Q4 2023 | +9.2% | +8.9% | -6.7% | |
| Q3 2023 | -6.6% | -19.8% | -38.8% | |
| Q2 2023 | -29.2% | -29.7% | -27.0% | |
| Q1 2023 | -0.5% | +0.2% | -12.1% | |
| Q4 2022 | -2.9% | -11.2% | +0.3% | |
| Q3 2022 | -3.8% | -4.2% | -10.4% | |
| Q2 2022 | -1.9% | -13.2% | -24.4% | |
| Q1 2022 | +2.8% | +1.8% | +3.9% | |
| Q4 2021 | +14.8% | +22.0% | +2.7% | |
| Q3 2021 | +5.6% | +6.3% | +35.8% | |
| Q2 2021 | -6.9% | -5.6% | -8.5% | |
| Q1 2021 | +3.1% | -3.3% | -3.9% | |
| Q4 2020 | -1.6% | -1.5% | -2.9% | |
| Q3 2020 | -2.1% | +0.2% | +4.4% | |
| Q2 2020 | -0.6% | +1.8% | -0.5% | |
| Q1 2020 | -0.1% | -5.4% | -2.3% | |
| Q4 2019 | -1.8% | +1.1% | +3.4% | |
| Q3 2019 | +6.0% | +7.4% | +0.7% | |
| Q2 2019 | -0.0% | -3.2% | +0.5% | |
| Q1 2019 | +11.6% | +11.2% | +22.9% | |
| Q4 2018 | +1.5% | +0.2% | -11.1% | |
| Q3 2018 | -6.4% | -6.3% | -11.4% | |
| Q2 2018 | -4.5% | -3.6% | +7.7% | |
| Q1 2018 | -19.0% | -16.7% | -7.5% | |
| Q4 2017 | -5.9% | -1.4% | +18.0% | |
| Q3 2017 | +2.2% | +2.0% | +11.6% | |
| Q2 2017 | +9.3% | +8.0% | -3.3% | |
| Q1 2017 | -6.5% | -7.5% | -8.9% | |
| Q4 2016 | +7.4% | +9.0% | +10.0% | |
| Q3 2016 | +2.3% | +6.4% | +4.3% | |
| Q2 2016 | -1.8% | — | — | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | -2.0% | — | — | |
| Q3 2015 | -13.8% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | -4.2% | — | — | |
| Q4 2014 | +4.3% | — | — | |
| Q3 2014 | +4.6% | — | — | |
| Q2 2014 | +5.2% | — | — | |
| Q1 2014 | -3.6% | — | — | |
| Q1 2013 | -3.6% | — | — | |
| Q4 2011 | -22.6% | — | — | |
| Q1 2012 | -22.6% | — | — | |
| Q4 2013 | +8.5% | — | — | |
| Q3 2013 | +7.4% | — | — | |
| Q3 2012 | +7.4% | — | — | |
| Q2 2012 | +5.5% | — | — | |
| Q4 2012 | +5.5% | — | — | |
| Q2 2013 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro